These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 15658422)

  • 21. Activated protein C resistance assay as a screening test for thromboembolic disposition.
    Shizuka R; Amagai H; Kojima J; Fukumura Y; Kanda T; Kobayashi I
    J Med; 1997; 28(5-6):381-6. PubMed ID: 9604796
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thrombotic tendency in 75 symptomatic, unrelated patients with APC resistance.
    Melichart M; Kyrle PA; Eichinger S; Rintelen C; Mannhalter C; Pabinger I
    Wien Klin Wochenschr; 1996; 108(19):607-10. PubMed ID: 8921576
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thrombotic risk factors and oral contraception.
    Bokarewa MI; Falk G; Sten-Linder M; Egberg N; Blombäck M; Bremme K
    J Lab Clin Med; 1995 Sep; 126(3):294-8. PubMed ID: 7665978
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activated protein C resistance and thrombosis: molecular mechanisms of hypercoagulable state due to FVR506Q mutation.
    Dahlbäck B
    Semin Thromb Hemost; 1999; 25(3):273-89. PubMed ID: 10443959
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Activated protein C resistance and venous thrombophilia: molecular genetic prevalence study in the German population].
    Ehrenforth S; Klinke S; von Depka Prondzinski M; Kreuz W; Ganser A; Scharrer I
    Dtsch Med Wochenschr; 1999 Jun; 124(25-26):783-7. PubMed ID: 10414227
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of functional testing for resistance to activated protein C and molecular biological testing for factor V R506Q in 370 patients.
    Montes MA; Fox EA; Longtine JA; Dorfman DM
    Arch Pathol Lab Med; 1998 Apr; 122(4):325-9. PubMed ID: 9648899
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Haemostatic changes and acquired activated protein C resistance in normal pregnancy.
    Mahieu B; Jacobs N; Mahieu S; Naelaerts K; Vertessen F; Weyler J; Jacquemyn Y; Van der Planken M
    Blood Coagul Fibrinolysis; 2007 Oct; 18(7):685-8. PubMed ID: 17890957
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Screening for a prothrombotic diathesis in patients attending family planning clinics.
    Kalev M; Day T; Van de Water N; Ockelford P
    N Z Med J; 1999 Sep; 112(1096):358-61. PubMed ID: 10587055
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Pulmonary embolism disclosing activated protein C resistance].
    Strecker A; Bernardi F; Wolschies E; Hendricx S; Jude B
    Rev Mal Respir; 1996 Oct; 13(5):521-2. PubMed ID: 8999481
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Deep venous thrombosis and thrombophilia: indications for testing and clinical implications.
    de Moerloose P; Alhenc-Gelas M; Boehlen F; Bounameaux H; Aiach M
    Semin Vasc Med; 2001; 1(1):89-96. PubMed ID: 15199518
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Measurement of activated protein C resistance during menstrual cycle in women with and without the Leiden mutation.
    Wramsby ML; Bremme K; Blombäck M
    Thromb Haemost; 2001 Apr; 85(4):614-8. PubMed ID: 11341494
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inherited thrombophilia and first venous thromboembolism during pregnancy and puerperium.
    Martinelli I; De Stefano V; Taioli E; Paciaroni K; Rossi E; Mannucci PM
    Thromb Haemost; 2002 May; 87(5):791-5. PubMed ID: 12038778
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low prevalence of factor V:Q506 in 41 patients with isolated pulmonary embolism.
    Martinelli I; Cattaneo M; Panzeri D; Mannucci PM
    Thromb Haemost; 1997 Mar; 77(3):440-3. PubMed ID: 9065990
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in the etiology and treatment of venous thromboembolism.
    Comp PC
    Adv Intern Med; 1999; 44():59-89. PubMed ID: 9929705
    [No Abstract]   [Full Text] [Related]  

  • 35. The HR2 haplotype of factor V: effects on factor V levels, normalized activated protein C sensitivity ratios and the risk of venous thrombosis.
    de Visser MC; Guasch JF; Kamphuisen PW; Vos HL; Rosendaal FR; Bertina RM
    Thromb Haemost; 2000 Apr; 83(4):577-82. PubMed ID: 10780320
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activated protein C resistance--a major risk factor for thrombosis.
    Rosén SB; Sturk A
    Eur J Clin Chem Clin Biochem; 1997 Jul; 35(7):501-16. PubMed ID: 9263726
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activated protein C resistance assay detects thrombotic risk factors other than factor V Leiden.
    Graf LL; Welsh CH; Qamar Z; Marlar RA
    Am J Clin Pathol; 2003 Jan; 119(1):52-60. PubMed ID: 12520697
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Laboratory diagnosis of resistance to activated protein C (APC-resistance).
    Bertina RM
    Thromb Haemost; 1997 Jul; 78(1):478-82. PubMed ID: 9198200
    [No Abstract]   [Full Text] [Related]  

  • 39. [Resistance to activated protein C. The most common cause of familial thrombophilia].
    Larsen TB; Ravn HB; Lassen JF; Lund ED; Brandslund I
    Ugeskr Laeger; 1996 Nov; 158(46):6584-8. PubMed ID: 8966822
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Resistance to activated protein C as risk factor for thrombosis: molecular mechanisms, laboratory investigation, and clinical management.
    Dahlbäck B
    Semin Hematol; 1997 Jul; 34(3):217-34. PubMed ID: 9241707
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.